Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31485757 | 0.78 | PLA2G2A (0.42) | LMNA | |
| SCHEMBL30460016 | 0.75 | KDM4E (0.47) | MAPTALDH1A1LMNACLK2 | |
| SCHEMBL26772813 | 0.73 | MAPT (0.33) | MAPT | |
| SCHEMBL22249932 | 0.72 | PIM1 (0.37) | MAPTALDH1A1LMNA | |
| SCHEMBL25490099 | 0.72 | LIMK1 (0.34) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL21398162 | 0.71 | CYP1A2 (0.43) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL16982279 | 0.71 | PLA2G2A (0.36) | MAPTALDH1A1LMNA | |
| SCHEMBL16982261 | 0.71 | PLA2G2A (0.33) | MAPTALDH1A1LMNAKMT2AGPR55 | |
| SCHEMBL22249678 | 0.70 | ALDH1A1 (0.61) | ALDH1A1LMNAKMT2AGPR55CLK2 | |
| SCHEMBL2628321 | 0.70 | GABRP (0.49) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022400-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022400-A1 | IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MAPT 4090/4885MAPK14 2103/4885PDE3B 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.